```html

White‑Footed Mouse Allergy (Mammalian Protein Allergy)

Overview

White‑footed mouse allergy, also known as mammalian protein allergy (MPA), is an immune‑mediated reaction to proteins found in the urine, saliva, dander, and skin flakes of certain rodents—most notably the North American white‑footed mouse (Peromyscus leucopus) and related species. The allergen that triggers the response is a protein called Mus m 1 (also known as “mouse urinary protein”). Although mouse allergy is less common than cat or dog allergy, it can cause severe respiratory and systemic symptoms, especially in children and individuals with a family history of atopy.

According to the CDC, rodent‑related allergies affect roughly 1–2 % of the U.S. population, with higher rates (up to 5 %) observed in rural households and in communities with high rodent exposure such as farms, grain‑storage facilities, and low‑income housing. The prevalence is believed to be under‑reported because many clinicians do not specifically test for mouse allergens.

Symptoms

Symptoms of MPA can appear within minutes of exposure or develop over several hours. The clinical picture often overlaps with other inhalant allergies, making it essential to recognize the pattern of exposure.

Respiratory

• Rhinitis: Sneezing, runny or congested nose, itchy throat.
• Asthma exacerbation: Wheezing, shortness of breath, chest tightness, cough that worsens at night or early morning.
• Allergic bronchopulmonary aspergillosis (rare): Persistent cough with mucus production.

Ocular & Facial

• Itchy, watery, or red eyes (allergic conjunctivitis).
• Swelling around the eyes or cheeks.

Skin

• Localized urticaria (hives) at sites of contact.
• Generalized pruritus (itching) without rash.
• Contact dermatitis from handling mouse bedding or droppings.

Systemic

• Anaphylaxis: Rapid onset of throat swelling, drop in blood pressure, dizziness, or loss of consciousness. This is rare but documented, especially in highly sensitized children.
• Fatigue, low‑grade fever, or malaise after prolonged exposure.

Causes and Risk Factors

MPA is an IgE‑mediated hypersensitivity reaction. The primary culprit is the protein Mus m 1, which is excreted in mouse urine and becomes airborne as tiny aerosolized particles. When inhaled, the protein can trigger the immune system in susceptible individuals.

Key Risk Factors

• Environmental exposure: Living in older homes with mouse infestations, working in laboratories, grain storage, or farms.
• Age: Children (especially 5–12 years) are more prone because their immune systems are still developing.
• Atopic history: Personal or family history of eczema, asthma, or other allergies increases susceptibility.
• Socioeconomic status: Overcrowded housing with poor rodent control is linked to higher sensitization rates.
• Occupational exposure: Laboratory technicians, pest control workers, and wildlife rehabilitators.

Diagnosis

Diagnosing MPA involves correlating clinical history with objective testing. Because mouse allergens are not part of standard allergy panels in many clinics, a targeted approach is required.

Clinical Evaluation

• Detailed exposure history (home, school, work, hobbies).
• Symptom diary linking flare‑ups to known mouse activity.

Allergy Testing

1. Skin Prick Test (SPT): Commercial extracts of mouse urine protein are applied to the skin. A wheal ≥3 mm larger than the negative control after 15 minutes suggests sensitization.
2. Specific IgE Blood Test: Measured with ImmunoCAP or similar platforms. Levels ≥0.35 kU/L are considered positive.
3. Component‑Resolved Diagnostics (CRD): Identifies IgE to the specific Mus m 1 component, improving specificity.

Environmental Assessment

• Air sampling in the home using mouse‑specific ELISA kits.
• Visual inspection for droppings, gnaw marks, and nesting material.

Rule‑out Other Conditions

Because symptoms overlap with other inhalant allergies, clinicians may test for cat, dog, dust mite, and cockroach allergens to differentiate or identify co‑sensitizations.

Treatment Options

Management combines pharmacologic therapy, allergen avoidance, and in selected cases, immunotherapy.

Medications

• Antihistamines: Second‑generation agents (cetirizine, loratadine, fexofenadine) for daytime symptoms; non‑sedating.
• Intranasal Corticosteroids: Fluticasone, mometasone, or beclomethasone spray for allergic rhinitis.
• Leukotriene Receptor Antagonists: Montelukast can help with both rhinitis and asthma.
• Bronchodilators: Short‑acting β2‑agonists (albuterol) for acute asthma symptoms; inhaled corticosteroids for persistent asthma.
• Epinephrine auto‑injector: Prescribed for patients with a history of systemic reactions or high specific IgE levels.

Allergen Immunotherapy (AIT)

While subcutaneous immunotherapy (SCIT) for mouse allergens is not FDA‑approved in the United States, several research centers in Europe and Australia have reported success with mouse‑specific extracts under investigational protocols. Candidates are typically adults with moderate‑to‑severe symptoms uncontrolled by medication and demonstrable IgE to Mus m 1.

Environmental Interventions

1. Integrated Pest Management (IPM): Seal entry points, eliminate food sources, use traps, and employ professional extermination.
2. HEPA Filtration: Portable air cleaners with HEPA filters can reduce airborne mouse allergen particles by up to 80 % (CDC, 2022).
3. Frequent Cleaning: Wet‑mopping floors, using a vacuum with a HEPA bag, and washing bedding in hot water (>130 °F).
4. Protective Equipment: Gloves and N‑95 respirators for workers cleaning infested areas.

Lifestyle Adjustments

Stress reduction, adequate sleep, and maintaining a healthy weight improve overall immune regulation and may lessen allergic reactivity.

Living with White‑Footed Mouse Allergy (Mammalian Protein Allergy)

Even after diagnosis and treatment initiation, day‑to‑day management is crucial.

• Allergy Action Plan: Keep a written plan that includes medication doses, trigger avoidance steps, and emergency contacts.
• Home Monitoring: Use a simple checklist to inspect for new mouse activity weekly.
• Pet Considerations: Some individuals react to multiple rodent proteins; avoid keeping pet rodents and ensure cats/dogs are not bringing in mouse dander.
• School & Workplace: Inform teachers, coaches, or supervisors about the allergy and request accommodations (e.g., regular cleaning, pest‑control contracts).
• Travel Tips: Pack a travel‑size HEPA air purifier for hotel rooms; request “pest‑free” rooms when booking.
• Medication Adherence: Use pill organizers or smartphone reminders to take daily antihistamines or inhaled steroids.
• Follow‑up Visits: Schedule allergy specialist appointments at least annually to reassess IgE levels and adjust therapy.

Prevention

Preventing sensitization is best achieved by reducing exposure before the immune system becomes primed.

1. Rodent Proofing: Install door sweeps, seal cracks, use steel‑wool and caulk around utility penetrations.
2. Food Safety: Store pantry items in airtight containers; clean up crumbs and spills promptly.
3. Proper Waste Management: Use tightly sealed trash cans and remove garbage regularly.
4. Regular Pest Inspections: Professional pest‑control services can detect early infestations and treat them safely.
5. Education: Community outreach programs in high‑risk neighborhoods have reduced rodent‑related allergies by up to 30 % (WHO, 2021).

Complications

If left untreated or poorly controlled, MPA can lead to:

• Chronic Asthma: Persistent airway inflammation may cause irreversible airway remodeling.
• Sinusitis: Ongoing rhinitis can lead to bacterial sinus infections.
• Sleep‑Disordered Breathing: Nasal congestion may exacerbate obstructive sleep apnea.
• Reduced Quality of Life: Daily symptoms can impair school performance, work productivity, and psychosocial wellbeing.
• Anaphylactic Shock: Though rare, systemic reactions can be life‑threatening without immediate epinephrine.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Allergy testing: Skin prick test.” 2023; CDC. “Rodent‑Associated Allergens.” 2022; National Institute of Allergy and Infectious Diseases (NIAID). “Mammalian Protein Allergy.” 2024; WHO. “Housing and Health: Controlling Indoor Allergens.” 2021; Cleveland Clinic. “Asthma and Allergies: Management.” 2023.

```